EXEL
EXELIXIS, INC.
NASDAQ · Healthcare · Biotechnology · US
$62.68
+0.72%Year over year
Reported trailing growth
- Revenue
- +9.2%
- EBITDA
- +28.1%
- EBIT
- +38.8%
- EPS
- +53.7%
- Free cash flow
- +60.2%
- Operating cash flow
- +53.3%
Forward estimates
Based on analyst estimates
- Revenue
- +13.1%
- EBITDA
- +23.7%
- EPS
- +15.9%
Three-year CAGR
- Revenue
- +12.9%
- EBITDA
- +53.4%
- EBIT
- +63.0%
- Net income
- +62.5%
- EPS
- +71.6%
- Free cash flow
- +55.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jul 1, 2026